Cargando…

Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination

BACKGROUND: Most poliovirus infections occur with no symptoms and this leads to the possibility of silent circulation, which complicates the confirmation of global goals to permanently end poliovirus transmission. Previous simple models based on hypothetical populations assumed perfect detection of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalkowska, Dominika A, Duintjer Tebbens, Radboud J, Pallansch, Mark A, Cochi, Stephen L, Wassilak, Steven G F, Thompson, Kimberly M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344758/ https://www.ncbi.nlm.nih.gov/pubmed/25886823 http://dx.doi.org/10.1186/s12879-015-0791-5

Ejemplares similares

Another look at silent circulation of poliovirus in small populations
por: Kalkowska, Dominika A., et al.
Publicado: (2018)

Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

An economic analysis of poliovirus risk management policy options for 2013–2052
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission
por: Duintjer Tebbens, Radboud J, et al.
Publicado: (2019)

The potential impact of expanding target age groups for polio immunization campaigns
por: Duintjer Tebbens, Radboud J, et al.
Publicado: (2014)

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

How should we prepare for an outbreak of reintroduced live polioviruses?
por: Thompson, Kimberly M, et al.
Publicado: (2017)

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2017)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Outbreak response strategies with type 2-containing oral poliovirus vaccines ()
por: Kalkowska, Dominika A., et al.
Publicado: (2023)

Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission
por: Thompson, Kimberly M., et al.
Publicado: (2017)

The impact of disruptions caused by the COVID-19 pandemic on global polio eradication()
por: Kalkowska, Dominika A., et al.
Publicado: (2023)

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy
por: DUINTJER TEBBENS, R. J., et al.
Publicado: (2017)

Potential Future Use, Costs, and Value of Poliovirus Vaccines
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Characterising the costs of the Global Polio Laboratory Network: a survey-based analysis
por: Duintjer Tebbens, Radboud J, et al.
Publicado: (2019)

Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV)
por: Thompson, Kimberly M., et al.
Publicado: (2019)

Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation
por: Kalkowska, Dominika A, et al.
Publicado: (2023)

Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters
por: Kalkowska, D. A., et al.
Publicado: (2019)

A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID‐19 in the United States
por: Thompson, Kimberly M., et al.
Publicado: (2020)

The re-emergence of wild poliovirus type 1 in Africa and the role of environmental surveillance in interrupting poliovirus transmission
por: Gwinji, Phanuel Tawanda, et al.
Publicado: (2022)

Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation
por: Thompson, Kimberly M., et al.
Publicado: (2023)

Contribution of Environmental Surveillance Toward Interruption of Poliovirus Transmission in Nigeria, 2012–2015
por: Johnson Muluh, Ticha, et al.
Publicado: (2016)

Environmental surveillance detects circulating vaccine-derived poliovirus type 2 that was undetected by acute flaccid paralysis surveillance in 2021 in Uganda
por: Tushabe, Phionah, et al.
Publicado: (2023)

Poliovirus seroprevalence before and after interruption of poliovirus transmission in Kano State, Nigeria
por: Iliyasu, Zubairu, et al.
Publicado: (2016)

Public Health Innovations on the Way to Interruption of Poliovirus Transmission in Nigeria
por: Vaz, Rui G., et al.
Publicado: (2016)

Possible Eradication of Wild Poliovirus Type 3 — Worldwide, 2012
por: Kew, Olen M., et al.
Publicado: (2014)

Outbreak of Type 2 Vaccine-Derived Poliovirus in Nigeria: Emergence and Widespread Circulation in an Underimmunized Population
por: Wassilak, Steven, et al.
Publicado: (2011)

Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States
por: Marin, Mona, et al.
Publicado: (2017)

Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–June 2019
por: Jorba, Jaume, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ocdtaih5c847t978t1ndf444vn